Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection

Ying Mu, Michelle Pham, Anthony T. Podany, Theodore J. Cory

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Introduction: Antiretroviral therapy (ART) is recommended for all people who are living with HIV to suppress viral load and to stop the progression and transmission of HIV-1. Fixed-dose combinations of antiretrovirals largely reduce pill burden. Areas covered: The authors first provide an overview of the use of non-nucleoside reverse transcriptase inhibitor (NNRTI) based therapy in HIV care. They then summarize the properties of each drug in the fixed-dose combination of tenofovir alafenamide/emtricitabine/rilpivirine/(TAF/FTC/RPV). The efficacy and safety of each component and the combination as a whole are reviewed: FTC is non-inferior to lamivudine (3TC) at assessed dosages; TAF was non-inferior to tenofovir disoproxil fumarate (TDF); the viral efficacy of RPV is non-inferior with EFV at the assessed dosage; TAF/FTC/RPV is non-inferior in efficacy but shows less of a decline in bone mineral density and renal function compared to TDF/FTC/RPV. Finally, adverse effects and drug–drug interaction data with FTC/RPV/TAF are discussed. Expert opinion: TAF/FTC/RPV can be used as an initial regimen for people living with HIV whose HIV RNA <100,000 copies/ml and CD4 cell count > 200 cells/mm3 when INSTI-based regimens are not a treatment option. Future antiretroviral therapy development may focus on dual therapy-based regimens containing RPV, particularly as long-acting formulations.

Original languageEnglish (US)
Pages (from-to)389-397
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume21
Issue number4
DOIs
StatePublished - Mar 3 2020

Keywords

  • Antiretroviral therapy
  • emtricitabine
  • rilpivirine
  • tenofovir alafenamide

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection'. Together they form a unique fingerprint.

  • Cite this